Advertisement
Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
440 dias atrás
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
474 dias atrás
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
621 dias atrás
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
1202 dias atrás
Fed's Beige Book Says U.S. Economic Activity Little Changed
Economic activity in the U.S. has shown little change since early September, according to the Federal Reserve's Beige Book.
RTTNews
|
29 minutos atrás
U.S. Mortgage Applications Fall For Third Week: MBA
Mortgage applications for house purchase in the U.S. decreased for a third week in a row, survey results from the Mortgage Bankers Association showed on Wednesday.
The market composite index, which measures the house purchase mortgage loan application volume, dropped a seasonally adjusted 1.8 percent in the week ended October 10 following a 4.7 percent decline in the previous week, results of th
RTTNews
|
2h 2min atrás
New York Manufacturing Index Unexpectedly Indicates Growth In October
New York manufacturing activity has seen a significant turnaround in the month of October, according to a report released by the Federal Reserve Bank of New York on Wednesday. The New York Fed said its general business conditions index surged to a positive 10.7 in October after plunging to a negative 8.7 in September, with a positive reading indicating growth.
RTTNews
|
4h 56min atrás
Bay Street Likely To Open Higher Again
Canadian shares are likely to open on a positive note Wednesday morning, tracking the firm trend in European markets, and higher commodity prices.
The undertone is likely to remain firm amid expectations of an interest rate cut by the Federal Reserve at its upcoming monetary policy meeting.
RTTNews
|
5h 58min atrás
